TITLE

Overt Gastrointestinal Bleeding in the Course of Chronic Low-Dose Aspirin Administration for Secondary Prevention of Arterial Occlusive Disease

AUTHOR(S)
Naschitz, Johanan E.; Yeshurun, Daniel; Odeh, Majed; Bassan, Harry; Rosner, Itzhak; Stermer, Edy; Levy, Nissim
PUB. DATE
April 1990
SOURCE
American Journal of Gastroenterology;Apr1990, Vol. 85 Issue 4, p408
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We describe 13 patients who developed erosive gastritis with overt gastrointestinal bleeding while receiving 75-250 mg nonbuffered aspirin per day for the secondary prevention of cardiac or cerebrovascular events. The bleeding occurred despite good initial tolerance to aspirin for several months or years. All patients were elderly and had severe atherosclerotic cardiovascular disease. Our data suggest that, contrary to common belief, very low doses of nonbuffered aspirin are attendant with clinically apparent gastrointestinal complications.
ACCESSION #
16018858

 

Related Articles

  • Independent Nurse: Aspirin 'no good for primary prevention'.  // GP: General Practitioner;9/11/2009, p8 

    The article reports that according to a new study in Great Britain, aspirin which is used for secondary prevention in patients with vascular disease, should not be recommended for the primary prevention of vascular events. The study, conducted by researchers from the University of Edinburgh,...

  • Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Tsai, Yi-Wen; Wen, Yu-Wen; Huang, Weng-Foung; Chen, Pei-Fen; Kuo, Ken; Hsiao, Fei-Yuan // Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p39 

    Background: Concomitant use of antiplatelet agents and proton-pump inhibitors (PPIs) has been recommended in patients with a history of gastrointestinal (GI) hemorrhage. However, recent studies have reported that PPIs may alter clopidogrel's pharmacokinetics and potentially lead to an increased...

  • Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study. Grove, Erik; Würtz, Morten; Schwarz, Peter; Jørgensen, Niklas; Vestergaard, Peter // JGIM: Journal of General Internal Medicine;Feb2013, Vol. 28 Issue 2, p216 

    BACKGROUND: Clopidogrel prevents cardiovascular events, but has been linked with adverse gastrointestinal (GI) complications, particularly bleeding events. OBJECTIVE: We aimed to investigate the risk of adverse GI events in patients treated with clopidogrel. DESIGN: A nationwide population-based...

  • Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study. Origasa, Hideki; Goto, Shinya; Shimada, Kazuyuki; Uchiyama, Shinichiro; Okada, Yasushi; Sugano, Kentaro; Hiraishi, Hideyuki; Uemura, Naomi; Ikeda, Yasuo // Cardiovascular Drugs & Therapy;Dec2011, Vol. 25 Issue 6, p551 

    Objective: Although aspirin has been widely prescribed for the prevention of cardiovascular events, its risk of gastrointestinal complications is of great concern. Despite expectations for such, few data are available on the prevalence or incidence of gastrointestinal complications in aspirin...

  • Bleeding risk outweighs aspirin's primary prevention benefit.  // Reactions Weekly;7/7/2012, Issue 1409, p5 

    The article reports on the findings of a study conducted in Italy which revealed that the use of aspirin for the prevention of cardiovascular events is linked to an increased risk of major gastrointestinal (GI) and intracranial bleeding. Researchers mentioned that major bleeding risk is not...

  • Aspirin overutilization for the primary prevention of cardiovascular disease. VanWormer, Jeffrey J.; Miller, Aaron W.; Rezkalla, Shereif H. // Clinical Epidemiology;2014, Vol. 6, p433 

    Background: Aspirin is commonly used for the primary prevention of cardiovascular disease (CVD) in the US. Previous research has observed significant levels of inappropriate aspirin use for primary CVD prevention in some European populations, but the degree to which aspirin is overutilized in...

  • Clopidogrel: convention not up to mark in bleeding ulcer prevention.  // Reactions Weekly;2/5/2005, Issue 1037, p4 

    Provides information on the effectivity of the combination of aspirin plus esomeprazole and clopidogrel in preventing the recurrence of bleeding in patients with ulcer. Number of patients who were observed; Difference between the clopidogrel group and the aspirin/esomeprazole group with regard...

  • News from the British Society of Gastroenterology meeting. . .  // Reactions Weekly;5/14/2005, Issue 1051, p3 

    Discusses research being done on Upper gastrointestinal (GI) haemorrhage associated with low dose aspirin and antithrombotic drugs. Reference to a study by A.S. Taha et al published in an April 2005 issue of "Gut" journal; Increase in the incidence of upper GI haemorrhage in British patients...

  • New dabigatran safety concerns. Garrett, Anna D. // Drug Topics;Apr2012, Vol. 156 Issue 4, p45 

    The article offers information on the safety concern over dabigatran, as new warnings are being added related to the risk of bleeding and myocardial infarction (MI) in patients. According to a study, dabigatran or warfarin are only for patients with atrial fibrillation (AF). It mentions that the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics